/
OUR BUSINESS KORU Medical develops, manufactures and commercializes innovative and patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market as governed by the United States Food and Drug Administration (the FDA ) quality and regulatory system and international standards for quality system management. Our focus is primarily concentrated on …
$4.07
$0.04 (-1.09%)
Live · 11:04 PM
The business is unprofitable at the operating level (-7.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 22.2% YoY with margins expanding 11.9pp.
Negative free cash flow of -$470K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$43M
▲ +22.2% YoY
Net Income (TTM)
-$2M
▲ +56.5% YoY
Op. Margin
-5.99%
▲ +11.9pp YoY
ROIC
-10.12%
▲ +11.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$179K
▲ +70.9% YoY
Op. Cash Flow (TTM)
$715K
▲ +244.6% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$9M
5Y CAGR: +11.2%
Continue Research
Koru Medical Systems (KRMD) trades above a two-stage DCF intrinsic value of about $0.21 per share, so at $4.07 the stock looks overvalued (94.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Koru Medical Systems scores 58/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $0.21 per share for KRMD, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $0.16. At today's $4.07, that puts the stock about 94.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Koru Medical Systems scores 58 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -6.0% operating margin and a -10.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. KRMD currently trades above its estimated intrinsic value and scores 58/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.